The possibility of using Atezolizumab to treat alveolar soft part sarcoma
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on September 20th, 2023
|
Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma that has a 5-year survival rate between 20% and 46%. Since there was not any approved therapy for ASPS, a study was conducted to investigate the potential usage of Atezolizumab, an immune checkpoint inhibitor that blocks programmed death ligand 1. Due to its promising result, Atezolizumab had been approved by the Food and Drug Administration as a treatment for ASPS.
The phase 2 clinical trial included 52 patients who had been diagnosed with ASPS but have not received any previous anti–PD-1 or anti–PD-L1 therapy. For participants above the age of 18 years old, Atezolizumab was used at a dose of 1200 mg; in the case of pediatric subjects, dose was calculated to be 15 mg per kilogram of body weight. Atezolizumab was administered intravenously once every 21 days. The median treatment duration was 13.2 months, but many participants were treated with Atezolizumab for more than 24 months. Using the standard set by the version 1.1 of the Response Evaluation in Solid Tumors (RECIST), the researchers observed that Atezolizumab reduced the tumor size in 18 of the patients, and completely removed tumors in 1 patient. It took approximately 3.6 months for the medication to act on the tumor, and Atezolizumab helped prevent disease progression in a median duration of 20.8 months. Most of the adverse events reported by the participants were mild to moderate, and the type of incidence was similar to previously reported data.
The phase 2 clinical trial included 52 patients who had been diagnosed with ASPS but have not received any previous anti–PD-1 or anti–PD-L1 therapy. For participants above the age of 18 years old, Atezolizumab was used at a dose of 1200 mg; in the case of pediatric subjects, dose was calculated to be 15 mg per kilogram of body weight. Atezolizumab was administered intravenously once every 21 days. The median treatment duration was 13.2 months, but many participants were treated with Atezolizumab for more than 24 months. Using the standard set by the version 1.1 of the Response Evaluation in Solid Tumors (RECIST), the researchers observed that Atezolizumab reduced the tumor size in 18 of the patients, and completely removed tumors in 1 patient. It took approximately 3.6 months for the medication to act on the tumor, and Atezolizumab helped prevent disease progression in a median duration of 20.8 months. Most of the adverse events reported by the participants were mild to moderate, and the type of incidence was similar to previously reported data.